Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRYZ | Q08257 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 6/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694534 | 0.86 | CRYZ (0.53) | CRYZCA12CA1CA2CA9 | |
| SCHEMBL6693338 | 0.79 | CRYZ (0.64) | CRYZPNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6690591 | 0.76 | CRYZ (0.67) | CRYZCA12CA1CA2CA9 | |
| SCHEMBL6691547 | 0.75 | CRYZ (1.00) | CRYZNPSR1KDM4EALOX15MAPK1 | |
| SCHEMBL6693341 | 0.75 | CRYZ (0.56) | CRYZPNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6690595 | 0.73 | CRYZ (0.62) | CRYZCA12CA1CA2CA9 | |
| SCHEMBL6693404 | 0.68 | CRYZ (1.00) | CRYZNPSR1KDM4EALOX15MAPK1 | |
| SCHEMBL6691548 | 0.68 | CRYZ (0.74) | CRYZCA12CA1CA2CA9 | |
| SCHEMBL6692264 | 0.65 | CRYZ (0.60) | CRYZNPSR1KDM4EALOX15MAPK1 | |
| SCHEMBL3602500 | 0.63 | TDP2 (0.47) | CA12CA1CA2CA9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | HU, LONGQIN | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | MKI67, NME2, NTPCR | CRYZ 1190/4885NPSR1 1115/4885CA12 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.